CoChat

Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)

Elbitar, Sandy, Khoury, Petra El, Ghaleb, Youmna, Rabès, Jean-Pierre, Varret, Mathilde, Seidah, Nabil G., Boileau, Catherine, Abifadel, Marianne · 2016 · Expert Opinion on Therapeutic Patents

The DOI matches its Crossref record; 100 of the 120 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The identification by Abifadel et al. in 2003 of the first mutations of PCSK9 was the major breakthrough in the cholesterol field that led to a new therapeutic target. This discovery paved the way to new lipid lowering drugs reducing LDL-cholesterol levels through the inhibition of PCSK9. Two anti-PCSK9 monoclonal antibodies have received FDA and EMA approvals: Alirocumab and Evolocumab. Areas covered: This article reviews the different strategies that are pursued to modulate the functional activity of PCSK9 for lowering LDL-cholesterol levels. It also provides a brief overview of the patents related to PCSK9 from 2011 until the end of 2015. This review is addressed to researchers from academia and pharmaceutical companies who are engaged in PCSK9 research/cholesterol regulation. Readers will gain an up-to-date overview of the different strategies that have been investigated to reduce PCSK9, focusing on anti-PCSK9 monoclonal antibodies and the related clinical trials. Expert opinion: Anti-PCSK9 antibodies are a new class of lipid lowering drugs with promising results in reducing LDL-cholesterol. Long-term ongoing studies investigating on a large scale the efficacy and safety of the anti-PCSK9 antibodies and their cardiovascular outcomes are eagerly awaited.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543776.2016.1206080

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Cited by

See all 30

Metadata

Authors
Elbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J.-P., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M.
Affiliations
  • Inserm (FR)
  • Université de Versailles Saint-Quentin-en-Yvelines (FR)
  • Montreal Clinical Research Institute (CA)
  • ,
Corresponding author
Abifadel, Marianne
Venue
Expert Opinion on Therapeutic Patents
Published
2016-07-12
Volume
26
Issue
12
Pages
1377-1392
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
OpenAlex
W2466927139
Cited by
29
References
120
Citations by year
2024: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 4
FWCI
0.95
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Patents (publishedVersion)
  • PubMed (publishedVersion)
Funders
Fondation-Leducq (FLQ # 13 CVD 03)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
PCSK9 inhibitors, PCSK9, anti-PCSK9 monoclonal antibodies, alirocumab, evolocumab, LDL cholesterol lowering, lipid-lowering drugs, PCSK9 mutations, cardiovascular outcomes, patent analysis
MeSH terms
Proprotein Convertase 9, PCSK9 Inhibitors, Animals, Antibodies, Monoclonal, Anticholesteremic Agents, Humans, Cholesterol, LDL, Mutation, Patents as Topic, Drug Design, Dyslipidemias, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.